

Sub
E.
cont.

inactivation; and (b) a thrombocyte activating stimulus selected from the group consisting of collagen, thrombin, trypsin, ADP, serotonin and adrenalin.

2. (twice amended) A medicinal product according to claim 1, wherein the content of thrombocytes or thrombocyte fragments is such that it corresponds to at least 10^4 thrombocytes per ml after reconstitution of the lyophilisate or thawing.

3. (twice amended) A medicinal product according to claim 1, wherein the medicinal product comprises additional growth factors.

4. (twice amended) A medicinal product according to claim 1, wherein the medicinal product comprises a cross-linkable human protein selected from the group consisting of fibrinogen, fibronectin, blood coagulation factor XIII and collagen.

5. (amended) A medicinal product according to claim 4, wherein the cross-linkable human protein has been subjected to a process selected from the group consisting of virus partitioning and virus inactivation.

6. (twice amended) A medicinal product according to claim 4, wherein the cross-linkable human protein is present in the lyophilized or frozen state.

7. (twice amended) A medicinal product according to claim 4 wherein the cross-linkable human protein is fibrinogen and the thrombocyte activating stimulus is thrombin.

8. (amended) A medicinal product according to claim 1, further comprising a tissue adhesive composed of fibrinogen-containing proteins and wherein the thrombocyte activating stimulus is thrombin.

9. (twice amended) A medicinal product according to claim 4, wherein the medicinal product additionally comprises a component selected from the group consisting of epithelial cells, keratinocytes, embryonic cells, fetal cells, liposomes and combinations thereof.

10. (twice amended) A method of promoting the healing of a wound in a subject, comprising (i) applying to the wound a composition comprising thrombocytes or thrombocyte fragments containing growth factors and capable of releasing the same over an extended period of time and (ii) applying to the wound a thrombocyte activating stimulus selected from the group consisting of collagen, thrombin, trypsin, ADP, serotonin and adrenalin.

Sub
E1
cont.

12. (amended) A medicinal product according to claim 5, wherein the cross-linkable human protein is present in the lyophilized or frozen state.

13. (amended) A medicinal product according to claim 5, wherein the cross-linkable human protein is fibrinogen and the thrombocyte activating stimulus is thrombin.

Q1
cont.

14. (amended) A medicinal product according to claim 6, wherein the cross-linkable human protein is fibrinogen and the thrombocyte activating stimulus is thrombin.

15. (amended) A medicinal product according to claim 1, further comprising a tissue adhesive composed of fibrinogen-containing proteins and wherein the thrombocyte activating stimulus is thrombin, and wherein the tissue adhesive and thrombin have been subjected to a process selected from the group consisting of virus partitioning and virus inactivation.

16. (amended) A medicinal product according to claim 1, further comprising a tissue adhesive composed of fibrinogen-containing proteins and wherein the thrombocyte-activating stimulus is thrombin, and wherein the tissue adhesive and thrombin are present in the lyophilized or frozen state.

17. (twice amended) A medicinal product according to claim 5, wherein the medicinal product additionally comprises a component selected from the group consisting of epithelial cells, keratinocytes, embryonic cells, fetal cells, liposomes and combinations thereof.

18. (twice amended) A medicinal product according to claim 6, wherein the medicinal product additionally comprises a component selected from the group consisting of epithelial cells, keratinocytes, embryonic cells, fetal cells, liposomes and combinations thereof.

19. (twice amended) A medicinal product according to claim 7, wherein the medicinal product additionally comprises a component selected from the group consisting of epithelial cells, keratinocytes, embryonic cells, fetal cells, liposomes and combinations thereof.

20. (twice amended) A medicinal product according to claim 8, wherein the medicinal product additionally comprises a component selected from the group